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Knockdown of TP53 in ASXL1 negative background
rescues apoptotic phenotype of human hematopoiet-
ic stem and progenitor cells but without overt malig-
nant transformation 
With increasing age, the incidence of haematological
malignancies rises, including myelodysplastic syndrome
(MDS). MDS is characterized by ineffective
hematopoiesis, a defect of differentiation in one or more
hematopoietic lineages, which can progress to acute
myeloid leukemia (AML) in time.1 Throughout the devel-
opment of MDS and AML, a vast subset of different driv-
er mutations can be identified that are prognostic for dis-
ease outcome. In low-risk MDS, frequently one driver
mutation can be recognized, which is accompanied by a
second mutation in the context of disease progression.1
Two genes that are found to be co-mutated in MDS
patients are ASXL1 and TP53.2 In patients, TP53 muta-
tions are often observed in complex karyotypes and pre-
dict unfavourable prognosis.2 Functional knockout stud-
ies of the mouse TP53 gene, Trp53, revealed resistance to
apoptosis after induced DNA damage.3 Mutations in
ASXL1 are also generally associated with an
unfavourable prognosis.4 Loss of function of the epige-
netic modifier ASXL1 in mice has been found to be
embryonic lethal and, after long latency, ASXL1 het-
erozygous mice developed MDS-like phenotypes.5
Additionally, ASXL1 loss leads to reduced numbers of
stem and progenitors in vitro and in vivo, accompanied by
increased apoptosis and decreased H3K27me3 levels.6,7
Nevertheless, malignant transformation has only been
observed in cells with altered genetic background, sug-
gesting that ASXL1 mutations need to be accompanied
by additional mutations.8
The aim of this study was to address whether simulta-
neous loss of ASXL1 and TP53 can rescue the adverse
phenotype in human hematopoietic stem and progenitor
cells (HSPC) upon ASXL1 knockdown and promote
transformation. 
To delineate the role of ASXL1 and TP53 loss in
hematopoiesis, we used an RNAi approach. We trans-
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Figure 1. Double loss of ASXL1 and
TP53 rescues replate potential of
colonies. (A) Gene expression hairpin #1
normalized to NACA and RPS11 (shown
are internal repeats) and protein levels.
(B) Gene expression hairpin #2 normal-
ized to NACA and RPS11 and protein lev-
els. (C) CFC analysis of CB cells express-
ing hairpin #1 shSCR/shSCR,
shSCR/shASXL1, shTP53/shSCR,
shTP53/shASXL1 (N=4). (D) CFC analy-
sis of CB cells expressing hairpin #2
shSCR/shSCR, shSCR/shASXL1,
shTP53/shSCR, shTP53/shASXL1
(N=3). (E) Cumulative cell count of
transduced CB cells cultured on MS5
stroma (N=3). (F) CFC colonies derived
of CB cells from MS5 co-cultures (N=3).
(G) CFC colonies derived from long-term
culture initiating cell assay (N=3). Error





duced CD34+ cord blood (CB) cells with control vectors
(shSCR/shSCR), knockdown of ASXL1 alone
(shSCR/shASXL1), knockdown of TP53 alone
(shTP53/shSCR), or double knockdown
(shTP53/shASXL1). Knockdown efficiency was deter-
mined for two independent hairpins using gene expres-
sion and western blot (Figure 1A,B). Efficacy of transduc-
tion were equal among hairpins, as shown in the Online
Supplementary Figure. GFP/mCherry double positive
CD34+ cells were sorted and plated into a colony-forming
assay (CFC) and demonstrated reduced CFC’s in the
ASXL1 transduced cells that could not be rescued by
additional knockdown of TP53 (Figure 1C,D). Upon
replating, granulocytic colony formation of the
TP53/ASXL1 double knockdown was enhanced four-fold
when compared to the control (hairpin #1 P<0.01; hair-
pin #2 P<0.001) and more than three-fold when com-
pared to ASXL1 and TP53 single knockdown (hairpin #1
P<0.05; hairpin #2 P<0.001). Subsequently, transduced
CD34+ CB cells were cultured in the context of stromal
micro-environment. Long-term stromal cultures with a
MS5 stromal layer were initiated, and a comparable
degree of expansion was observed in the different sub-
groups of transduced cells (Figure 1E). At week 1, cells
taken from suspension and plated in CFC demonstrated
a strong decline of CFU-GM numbers in the shASXL1
cells, which could be rescued by additional down-regula-
tion of p53 (Figure 1F). Next, we used the long-term cul-
ture initiating cell (LTC-IC) assay as a read-out for the
ability of HSPC to form colonies after an extended period
in culture (Figure 1G). The data shows that loss of ASXL1
significantly reduces the cobblestone forming potential
(nine-fold difference, control vs. shASXL1, P<0.05) and,
with additional knockdown of TP53, rescues the pheno-
type (six-fold difference, shASXL1 vs. shASXL1/shTP53,
ns). Taken together, these data demonstrate that an addi-
tional knockdown of TP53 with ASXL1 gives advantage
to HSPCs. 
Following the detrimental effects of ASXL1 knock-
down alone on erythroid colony formation (Figure 1C),
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Figure 2. TP53 knockdown partially rescues
shASXL1 induced apoptotic phenotype of
erythroid cells. (A) Cumulative cell count of
transduced CB cells cultured under erythroid
permissive conditions (N=3). (B) Total per-
centage of Annexin V+ cells at day 10 in ery-
throid liquid cultures (N=3). (C) Percentage
of erythroid differentiating cells at different
stages and their percentage of Annexin V+ at
day 10 of erythroid liquid cultures (N=3). (D)
Gene expression of ASXL1 and TP53 normal-
ized to NACA and RPS11 at 48hours (N=2)
and day 7 of erythroid liquid cultures (N=4).
(E) Gene expression normalized to NACA and
RPS11 at day 7 of erythroid liquid cultures
(N=4). Error bars represent standard devia-





shASXL1 and shTP53/shASXL1 CD34+ cells were cul-
tured under erythroid permissive conditions. Persistent
during culturing, shTP53/shASXL1 cells had a growth
advantage over shASXL1 cells (Figure 2A). On day 24,
cells with a double knockdown had a similar cumulative
cell count to control cells and a significantly higher cell
count than ASXL1 single cells (P<0.05). The knockdown
of ASXL1 was accompanied with an increase in Annexin
V+, which was rescued with additional knockdown of
TP53 (Figure 2B, day 10, shSCR/shASXL1 vs.
shTP53/shASXL1, P<0.05). 
Throughout erythroid differentiation, cells pass
through several stages of maturation. Immature cells dif-
ferentiate from the CD71mid compartment towards the
CD71bright, CD71bright/GPA+, and GPA+, the final erythroid
stadium. At day 10, cells with double knockdown of
TP53 and ASXL1 revealed a significantly greater percent-
age of CD71mid cells compared to controls and shTP53
cells (Figure 2C, P<0.05). The apoptotic phenotype of
ASXL1 single knockdown was significantly rescued with-
in the CD71mid compartment (Day 10, shSCR/shSCR vs.
shTP53/shASXL1, P<0.05) and CD71bright
(shSCR/shASXL1 vs. shTP53/shASXL1 P<0.01) (Figure
2C). A stable reduction in gene expression was observed
in time (Figure 2D). Further, knockdown of ASXL1 was
associated with the upregulation of HOXA9 and with the
down-regulation of BNIP3L, GATA2, and PIM1 (Figure
2E), which could partially be rescued in double trans-
duced cells. When looking at potential p53 downstream
targets that could be involved in the rescue (Day 7), BCL2
appeared to be significantly changed (Figure 2E). These
findings suggest that the favourable phenotype of
shTP53/shASXL1 is at least due to reduced apoptosis and
not to alterations in the epigenetic up-make in view of
the persistent elevated expression of HOXA9.
Previously, our lab and others reported that by using a
human scaffold setting, leukemic properties can be better
maintained within a human niche than a mouse niche.9
We therefore argued that a human microenvironment
within a mouse might be optimal for cell survival and
possibly malignant transformation. To this end, we trans-
duced CD34+ CB cells with shTP53/shASXL1, injected
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Figure 3. Humanized bone marrow-like niche in the mouse does not lead to transformation of cells with double knockdown. (A) Graphic overview of experi-
mental set-up. Scaffold 1-3 injected with cells, scaffold 4 no cells as empty control. (B) FACS plot of transduction efficiency of shTP53 and shASXL1 at day of
injection. (C) Percentage of human engraftment in the blood for six mice. Cage: 1 or 2; cut ear: L=left; R=right; NC=no-cut. (D) Percentage human engraftment






them directly into three scaffolds per mouse (n=6), bled
the mice in intervals and sacrificed them after 48 weeks
(Figure 3A). Remaining transduced CD34+ CB cells were
sorted for RNA to determine knockdown efficiency.
Figure 3B shows the sorting gates, which were equally
divided between the double knockdown and the ASXL1
single knockdown. Engraftment of human CD45+ cells
was low throughout maturing of the mouse and declined
after 34 weeks (Figure 3C). After sacrificing, bone mar-
row, spleen and liver were examined for human engraft-
ment, and the TP53 (GFP)/ASXL1 (mCherry) percentage
in the bone marrow, liver and spleen was analysed
(Figure 3D). Additionally, scaffolds were embedded and
examined for the presence of CD45+ cells but only few
CD45+ cells could be found within the scaffolds (Figure
3E). 
In this study, we demonstrated that TP53 rescued par-
tially the ASXL1 phenotype by affecting the apoptotic
programming without triggering malignant transforma-
tion. 
Recent studies of clonal hematopoiesis in healthy
donors demonstrated that ASXL1 and TP53 mutated cells
might persist in bone marrow without overt evolution to
MDS unless three or more mutations are present.2,10
These findings are in line with recent sequence data in
MDS, particularly in high-risk MDS, that three or more
mutations are frequently noticed, which might explain
why in our model stem cell properties are affected but
show no signs of transformation.11
Mutations in the ASXL1 gene generate a loss of func-
tion suggesting that the RNAi approach might be an
appropriate way to mimic patient setting. However,
recent studies have demonstrated that an overexpression
of mutated ASXL1 proteins can act within the PR-DUB
pathway and globally erase and diminish H2AK119ub
and H3K27me3, respectively.12 Similar TP53 mutations
are also associated with loss of function, but recent stud-
ies have demonstrated that mutated p53 protein can also
have additional functions by directly targeting chromatin
modifiers and by affecting the proteasome gene tran-
scription.13,14 Therefore, a combined knockdown of
ASXL1 and TP53 may not reflect the total mutational sta-
tus observed in MDS or AML. Furthermore, the order of
mutation may play a crucial role in what phenotype cells
present with. Ortmann et al. discovered that TET2 muta-
tions preceding JAK2 V617F heavily influenced the JAK2
V617F activated transcriptional program.15 The order of
mutation appeared to be of such importance that it
affected the clonal evolution in patients. In this study, we
simultaneously abrogated ASXL1 and TP53 function; in
the future, an alternative approach might be used. In
summary, our data demonstrate that ASXL1-compro-
mised cells benefit from loss of TP53 but do not lead to
malignant transformation. 
Susan Hilgendorf and Edo Vellenga
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